Publications by authors named "Harry Fagan"

Claim this Profile
O
Orexin receptor antagonists: Potential as novel antidepressants and anxiolytics.
Harry A Fagan, David S Baldwin

Eur Neuropsychopharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders.
Miriam A Schiele, Harry A Fagan, David S Baldwin, Katharina Domschke

Psychother Psychosom· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeing the bigger picture: endogenous opioids mediate attentional broadening after reward receipt.
Henk van Steenbergen, Philip Gable, Harry Fagan, Laura Molteni, Algirdas Midveris

Psychol Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo Effects Are Small on Average in the 7.5% CO2 Inhalational Model of Generalized Anxiety.
Nathan T M Huneke, Cosmina Cross, Harry A Fagan, Laura Molteni, Naomi Phillips

Int J Neuropsychopharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline.
Katharina Domschke, Patrik D Seuling, Miriam A Schiele, Borwin Bandelow, Neeltje M Batelaan, Harry Fagan

World Psychiatry· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the orexin system in the neurobiology of anxiety disorders: Potential for a novel treatment target.
Harry A Fagan, Nathan T M Huneke, Katharina Domschke, David S Baldwin

Neurosci Appl· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.
Harry A Fagan, David S Baldwin

Expert Rev Neurother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
Harry Fagan, Edward Jones, David S Baldwin

CNS Drugs· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review.
Nathan T M Huneke, Ibrahim H Aslan, Harry Fagan, Naomi Phillips, Rhea Tanna

Int J Neuropsychopharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obsessive-compulsive symptoms and the Covid-19 pandemic: A rapid scoping review.
Jon E Grant, Lynne Drummond, Timothy R Nicholson, Harry Fagan, David S Baldwin

Neurosci Biobehav Rev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases.
Ioannis Akoumianakis, Fabio Sanna, Marios Margaritis, Ileana Badi, Nadia Akawi, Harry Fagan

Sci Transl Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis